tional roles of the hexosamine biosynthetic pathway (HBP) in regulation of cardiovascular functions. The HBP flux is activated in hyperglycemic conditions, in which HBP is diverted from glycolysis, whereby fructose-6-phosphate, which is derived from glucose-6-phosphate, is converted to glucosamine-6-phosphate by the rate-limiting enzyme l-glutamine:d-fructose-6-phosphate amidotransferase (GFAT) in the presence of glutamine. 16 Glucosamine-6-phosphate is further converted to N-acetylglucosamine-6-phosphate (GlcNAc-6-p) and finally to UDP-GlcNAc, which serves as the monosaccharide donor for O-linked attachment of O-GlcNAc to serine/threonine residues of cellular proteins, leading to post-translational modifications and functional alterations of the proteins. The O-GlcNAc modification of cellular proteins, that is, O-GlcNAcylation, is determined by two enzymes: O-GlcNAc transferase (OGT), which adds, and O-GlcNAcase, which removes, O-GlcNAc to and from proteins, respectively. 16 Interestingly, the HBP is not only activated in hyperglycemic conditions, 17,18 but is also activated in hypoglycemic conditions, 19 in aging, heart ischemia, and in response to the vasoconstrictor endothelin-1, 17,20, 21 and to many other stressors including heat shock, UV radiation, ethanol, hypoxia, oxidative, and osmotic stress. 22 The HBP is therefore considered as a common stress signal in cells subjected to various stressors. 16 The functions under these conditions seem not entirely clear. Enhanced HBP flux can be achieved pharmacologically by glucosamine (GlcN), which bypasses GFAT and enters the HBP by formation of glucosamine-6-phosphate in the cells. GlcN is used as a dietary supplement and clinically used as a supplement to treat osteoarthritis despite uncertain efficacy. 23 Moreover, adverse effects on the cardiovascular system have also been reported. Studies demonstrate that activation of the HBP under diabetic and hyperglycemic conditions results from oxidative stress, leading to O-GlcNAcylation of eNOS and inhibition of eNOS enzymatic activity, 24, 25 and O-GlcNAcylation of Sp1 transcription factor enhances PAI-1 expression in endothelial cells. 24, 26 Importantly, animal experiments show that treatment of low density lipoprotein receptor (LDLR) -/-or apolipoprotein E (ApoE) -/-mice with GlcN accelerates atherosclerosis. [27] [28] [29] Recent studies have indicated that the protein kinase p38 mitogen-activated protein kinase (p38 mapk) is involved in the HBP. It has been shown that OGT activity in the HBP is dependent on p38 mapk in Neuro-2a neuroblastoma cells. 30 Conversely, O-GlcNAc seems also to be able to activate p38 mapk. 16, 31 The aim of the present study was to investigate the critical role of p38 mapk in GlcN-induced PAI-1 expression and eNOS uncoupling in endothelial cells and in isolated mouse aortas.
Methods
Materials RPMI-1640 was purchased from Amimed (Muttenz, Switzerland); Dulbecco Modified Eagle Medium (DMEM)-low glucose, Trypsin-EDTA and D-glucosamine hydrochloride were purchased from Sigma (Buchs, Switzerland); p38 mapk inhibitor SB203580 (4-[4-Fluorophenyl]-2-[4-methylsulfinylphenyl]-5-[4-pyridyl]1H-imidazole) and MEK inhibitor PD98059 (2'-Amino-3'-methoxyflavone) were purchased from Calbiochem (Lucerne, Switzerland); JNK inhibitor SP600125 (Anthra [1,9- cd]pyrazol-6(2H)-one 1,9-pyrazoloanthrone) was from ANAWA Trading SA (Wangen, Switzerland); Bio-Rad DC TM protein assay kit was from Bio-Rad Laboratories (Basal, Switzerland); MG-132 was from Alexis Enzo Life Sciences (Lausen, Switzerland); rabbit anti-T202/Y204-p44/42 ERK , rabbit antiphospho-c-Jun-S63, rabbit anti-CREB-S133, rabbit anti-IκB, rabbit anti-phospho-p38 mapk (pThr-180/pTyr-182) and mouse anti-p38 mapk antibodies were from Cell Signaling Technology (Allschwil, Switzerland); anti-plasminogen activator inhibitor-1 antibody (anti-PAI-1, H135) was purchased from Santa Cruz Biotechnol (Basel, Switzerland); anti-α-tubulin antibody was from Sigma (Buchs, Switzerland); anti-mouse and anti-rabbit IgG (H+L) alkaline phosphatase (AP) conjugate antibody and Western Blue ® (5-bromo-4-chloro-3-indolylphosphate and nitro blue tetrazolium) stabilized substrate for AP from Promega (Wallisellen, Switzerland). Alexa Fluor680-conjugated anti-mouse IgG (A21057), dihydroethidium (DHE) were from Molecular Probes/Invitrogen (Lucerne, Switzerland), and IRDye800-conjugated anti-rabbit IgG (926-32211) was from LI-COR Biosciences (Bad Homburg, Germany); the membrane-permeable 4,5-diaminofluoresceine acetate (DAF-2DA) was from VWR international SA (Dietikon, Switzerland); endothelial cell growth supplement pack was from PromoCell (Allschwil, Switzerland) and all cell culture media and materials were purchased from Gibco BRL (Lucerne, Switzerland).
Cultivation of Human Umbilical Vein Endothelial Cells (HUVECs)
Endothelial cells were isolated from human umbilical veins and cultured as previously described. 32 Cells at passage 2-4 were used. For the experiments, cells were cultured in DMEM containing 5.5 mmol/L of glucose and 0.2% BSA overnight prior to stimulation with GlcN alone or in combination with TNF-α (1 ng/ml) at different time points or concentrations of GlcN as indicated in the figures.
Immunoblotting for PAI-1 Expression and Activation of p38 mapk
Cell lysate preparation, SDS-PAGE, and transfer of SDS gels to an Immobilon-membrane were performed as previously described. 32 Briefly, the membranes were incubated with the rabbit anti-PAI-1 antibody at a dilution of 1:200 overnight at 4°C with continuous agitation after being blocked with blocking buffer. For analysis of protein kinases, the quiescent endothelial cells were incubated with 5 mmol/L of GlcN for the indicated time and subjected to immunoblotting analysis with the antibody against phospho-p38 mapk (Thr-180/Tyr185) as well as total p38 mapk (1:1,000). After washing, the membranes were incubated for 2 h either with an AP-conjugated anti-rabbit secondary antibody and signals were detected using Western Blue TM stabilized substrate, or incubated with a corresponding anti-mouse (Alexa fluor 680 conjugated) or antirabbit (IRDye 800 conjugated) secondary antibody, and signals were visualized using Odyssey Infrared Imaging System (LI-COR Biosciences). Quantification of the signals was performed using NIH Image 1.62 software. To normalize the PAI-1 protein level, the membrane was probed with a mouse anti-α-tubulin antibody. PAI-1 level was quantified as the ratio of PAI-1/tubulin, and activation of p38 mapk was presented as the ratio of phospho-p38 mapk to total p38 mapk.
Endothelium-Dependent and -Independent Responses in Isolated Mouse Aortas
For the in vitro experiments with isolated blood vessels, C57BL/6J wild-type male mice (3-5 months) fed on chow diet ad libitum were anesthetized with xylazin (10 mg/kg body weight, i.p.) and ketamin (100 mg/kg body weight, i.p.) and killed. The thoracic aortas were removed, placed into cold (4°C) Krebs bicarbonate solution, and dissected free from fat Glucosamine, p38mapk, and eNOS Uncoupling and adhering perivascular tissue, and subjected to organ chamber experiments and en face staining as previously described. 33 All the animal work was approved by the Ethics Committee of Veterinary Office of Fribourg, Switzerland and was performed in compliance with guidelines on animal experimentation at University of Fribourg.
The aortas with endothelium were cut into rings (3 mm in length) and suspended in a modified Krebs-Ringer bicarbonate solution aerated with 95% O2 and 5% CO2 at 37°C in a MultiMyograph System (Model 610 M, Danish Myo Technology, Denmark) in parallel. The aortic rings were allowed to equilibrate for 30 min and progressively stretched to a passive tension of 5 mN, which gives the optimal length-tension combination. To test the endothelium-dependent or -independent relaxations, one ring was pretreated with p38 mapk inhibitor (SB203580, 10 μmol/L) or with tiron (10 mmol/L) for 30 min. The aortic rings were then incubated with 5 mmol/L of GlcN for 1 h. The aortic rings were then contracted with norepinephrine (0.3 μmol/L). After the norepinephrine-induced contraction reached a plateau, cumulative concentration-response to acetylcholine (ACh; 1 nmol/L-10 μmol/L) or to the NO donor sodium nitroprusside (SNP; 0.1 nmol/L-3 μmol/L) was measured in each aortic ring.
En Face Confocal Detection of O2 .-and NO in Mouse Aortas
NO and superoxide production in the absence or presence of GlcN and/or inhibitors (p38 mapk inhibitor SB203580 or eNOS inhibitor N ω -nitro-l-arginine methyl ester (L-NAME)) was assessed with DAF-2DA and DHE staining, respectively, as described. 34 Briefly, mouse aortas cleaned of perivascular tissues were equilibrated for 30 min in Krebs buffer at 37°C aerated with 95% O2 and 5% CO2. After equilibration, SB203580 (10 μmol/L) was added in one ring for 30 min, and GlcN (5 mmol/L) was added to respective blood vessels for 1 h. DAF-2DA (5 μmol/L) or DHE (5 μmol/L) was then added for 30 min. For the functional eNOS uncoupling experiment, the aortas were treated as already described, except that L-NAME (1 mmol/L) was added to the blood vessels for 30 min before GlcN treatment, followed by staining with DAF-2DA (5 μmol/L) or DHE (5 μmol/L) for 30 min. The aortas were then washed three times and fixed in 4% paraformaldehyde for 15 min followed by counterstaining with DAPI (300 nmol/L, 2 min). After washing with PBS, the aortas were carefully cut longitudinally and mounted en face (face down) on a slide and then covered with cover slip for endothelial layer imaging. Vectashield mounting medium was used to preserve the fluorescence. Fluorescence was analyzed using a Leica DM6000 confocal microscope within hours after preparation. Fluorescence from DAF-2DA staining was produced with a 488-nm argon laser with emission detection at 500-535 nm, whereas fluorescence from DHE was detected at 590 nm emission. Zscanning was done for each sample. After the signal on the top (endothelial layer on the lumen border) of the sample was observed, the images were collected. Three consecutive images per field, acquired through the full thickness of endothelial signal, were recorded for analysis. At least 3 different fields per sample were evaluated. The images from DAF-2DA, DHE and DAPI staining were quantified with Image J 
Statistical Analysis
Data are presented as mean ± SEM. The statistical analysis of difference between control and test groups was performed using one-way ANOVA with Bonferroni post test. P<0.05 was considered to be statistically significant.
Results

GlcN Enhances PAI-1 Protein Level in Endothelial Cells: Potentiated by TNF-α
Incubation of endothelial cells with GlcN at concentrations ranging from 0.01 to 10 mmol/L over 24 h concentration dependently enhanced PAI-1 protein level ( Figure 1A) . Moreover, time course experiment showed that the PAI-1 expression stimulated by GlcN increased significantly at 2 h by 3.9-fold, reached a maximum effect at 8 h, and was maintained up to 24 h (Figure 1B Figure S1 ), did not affect GlcN's effect on PAI-1 expression, whereas the p38 mapk inhibitor SB203580 (10 μmol/L) which efficiently inhibits p38 mapk signaling (Figure S1 ), abolished the GlcN-mediated increase in PAI-1 expression in the endothelial cells (Figure 2 ; P<0.05 vs. GlcN), demonstrating the involvement of p38 mapk in PAI-1 expression stimulated by GlcN. Similarly, the enhancing effect of TNF-α (1 ng/ml, 24 h) on PAI-1 expression in response to GlcN (5 mmol/L) was also reduced by the p38 mapk inhibitor SB203580 (10 μmol/L, Figure 2 ; P<0.001 vs. GlcN plus TNF-α), whereas inhibitors of MEK or JNK had no significant effects (Figure 2 ). The results demonstrate that PAI-1 expression either stimulated by GlcN alone or potentiated by TNF-α is dependent on p38 mapk. Notably, GlcN or TNF-α (1 ng/ml) alone induced a transient activation of p38 mapk in the endothelial cells over 60 min (Figure 3) . A Figure 2 . Inhibition of p38 mitogen-activated protein kinase (p38 mapk) prevents endothelial plasminogen activator inhibitor-1 (PAI-1) expression in response to glucosamine (GlcN) and/or tumor necrosis factor (TNF)-α. The endothelial cells were pre-treated with the respective mitogen-activated protein kinase inhibitors for 1 h followed by stimulation either with (green) glucosamine alone (GlcN, 5 mmol/L, 24 h) or by (red) the combination of GlcN (5 mmol/L) plus TNF-α (1 ng/ml) for 24 h. PD, PD98059, a MEK inhibitor; SB, SB203580, a p38 mapk inhibitor; SP, SP600125, a JNK inhibitor. n=4, **P<0.01 vs. control; † † P<0.01 vs. GlcN; ¶ P<0.05 vs. GlcN alone; ¶ ¶ ¶ P<0.001 vs. GlcN plus TNF-α. Figure 3 . Activation of p38 mitogen-activated protein kinase (p38 mapk) by glucosamine (GlcN) and tumor necrosis factor (TNF)-α. Time course of p38 mapk activation by GlcN (5 mmol/L), TNF-α (1 ng/ml) or the combination of both over 60 min. n=3. ***P<0.001 vs. GlcN or TNF-α alone at 15 min. Glucosamine, p38mapk, and eNOS Uncoupling synergistic stimulation of p38 mapk activation by GlcN and TNF-α was observed at 15 min (Figure 3) .
Inhibition of p38 mapk Prevents Endothelial Dysfunction Mediated by GlcN
In mouse aortic rings with endothelium contracted with norepinephrine (0.3 μmol/L), the endothelium-dependent relaxations in response to acetylcholine (1 nmol/L-10 μmol/L) were inhibited by pre-incubation of the aortic rings by GlcN (5 mmol/L) for 1 h (Figure 4 ; P<0.05 vs. GlcN treatment). The inhibitory effect of GlcN on the endothelium-dependent relaxations was fully prevented by the p38 mapk inhibitor SB203580 (10 μmol/L) and only partly prevented by the reactive oxygen species (ROS) scavenger tiron (10 mmol/L) at a concentration that has been shown to fully inhibit ROS generation in endothelial cells. 34 The endothelium-independent relaxations in response to the NO donor SNP were not affected under these conditions (Figure 4) .
Inhibition of p38 mapk Prevents eNOS Uncoupling Induced by GlcN
To further investigate the mechanism by which p38 mapk inhibitor prevents endothelial dysfunction caused by GlcN, we examined the effect of GlcN and p38 mapk inhibitor on eNOS uncoupling. Mouse aortas were pretreated with p38 mapk inhibitor SB203580 (10 μmol/L) for 30 min, followed by GlcN treatment (5 mmol/L) for 1 h as described; O2 .-and NO production were then determined on DHE and DAF-2DA staining, respectively. GlcN increased O2 .-and decreased NO production, and these effects of GlcN were prevented by the p38 mapk inhibitor SB203580 (Figure 5A) . The increase in O2 .-production by GlcN was abolished by the eNOS inhibitor L-NAME (1mmol/L, Figure 5B ). Taken together, these results demonstrate that GlcN causes eNOS uncoupling through the p38 mapk pathway.
Discussion
Endothelial dysfunction and increased PAI-1 levels are common under various pathological conditions such as diabetes and atherosclerosis. 8, 9 Inflammation and oxidative stress are the main mechanisms of endothelial dysfunction and PAI-1 expression under these disease conditions. 35,36 Previous studies have shown that the pro-inflammatory cytokine TNF-α either alone or together with high glucose has detrimental effects on endothelial cells, such as oxidative stress, impairment of endothelium-dependent relaxation, and augmentation of endothelial adhesion molecule expression for leukocytes. 24,37, 38 There is substantial evidence demonstrating that the HBP mediates many deleterious effects of diabetes, including insulin resistance, oxidative stress, enhanced PAI-1 expression, and endothelial dysfunction. 17,39, 40 As a consequence, enhanced HBP flux has been shown to accelerate atherogenesis in LDLR-/-and ApoE-/-mice. 24,27-29, 41 In line with these studies, the present study further demonstrates a synergistic effect of TNF-α and GlcN on endothelial PAI-1 expression. This effect of TNF-α and GlcN is dependent on the p38 mapk pathway, because inhibition of p38 mapk but not MEK or JNK reduced PAI-1 expression. Indeed, activation of p38 mapk by the HBP has been reported in mesangial cells, leading to PAI-1 gene expression. 31 In the present study we detected a transient activation of p38 mapk by GlcN, which was potentiated There are studies showing that p38 mapk activates OGT in the HBP, leading to enhanced O-GlcNAcylation of proteins. 30 It is unlikely, however, that in the present experimental setting, TNF-α enhances GlcN-induced PAI-1 expression through augmentation of increased OGT activity, because our previous study showed no further increase in O-GlcNAcylation of cellular proteins in endothelial cells exposed to TNF-α, 38 although O-GlcNAcylation of certain proteins could not be fully excluded.
One of the important novel findings of the present study is that activation of the HBP by GlcN causes eNOS uncoupling through p38 mapk, thereby impairing endothelium-dependent relaxations in mouse aortas. The detrimental effect of the HBP Figure 5 . Inhibition of p38 mitogen-activated protein kinase (p38 mapk) prevents glucosamine (GlcN)-induced endothelial nitric oxide synthase uncoupling. Confocal microscopic en face detection of endothelial NO production and reactive oxygen species generation by DAF-2DA and DHE staining, respectively, followed by counterstaining with DAPI for endothelial nuclei in the intact thoracic aorta segments from C57BL mice. (A) Aortas were treated with GlcN in the absence or presence of p38 mapk inhibitor SB SB203580 as described in Figure 4. (B) Aortas were treated with GlcN (5 mmol/L, 1 h) in the absence or presence of N ω -nitrol-arginine methyl ester (L-NAME) (1 mmol/L) prior to en face staining. Quantification of the fluorescence intensity normalized by DAPI is presented in the corresponding right panels. Scale bar, 100 μm. n=4, *P<0.05 and **P<0.01 between the indicated groups. Glucosamine, p38mapk, and eNOS Uncoupling on endothelial function has been reported in numerous previous studies that demonstrated that enhanced HBP flux impairs endothelial function through post-translational O-GlcNAcylation of Akt, an upstream kinase for eNOS activation. 41 In the present study we described a further mechanism of endothelial dysfunction caused by the HBP. Our previous study showed that activation of the HBP by GlcN enhances superoxide production in cultured endothelial cells. 42 The pro-oxidative effect of GlcN has also been shown in renal mesangial cells, pancreas β-cells. 43 , 44 The present study showed that the enhanced O2 .-generation by GlcN in endothelial cells is attributed to eNOS uncoupling, because the increased O2 .-generation by GlcN is abolished by the eNOS inhibitor, L-NAME. Importantly, in situ production of O2 .-in isolated mouse aortas caused by GlcN is inhibited and NO production restored by p38 mapk inhibitor, which is paralleled with restoration of endothelium-dependent relaxation in isolated mouse aortas. These results demonstrate that the HBP causes eNOS uncoupling through p38 mapk. It should be noted that the impairment of endothelium-dependent relaxations is only partly prevented by the ROS scavenger tiron at a concentration of 10 mmol/L, which was shown to fully inhibit ROS generation in endothelial cells. 36 This indicates that besides eNOS uncoupling, other mechanisms that are also activated by p38 mapk, are involved in GlcN-induced endothelial dysfunction. The results suggest that inhibition of p38 mapk signaling represents a more powerful means of improvement of endothelial dysfunction than inhibition of oxidative stress.
These results shed new light on the mechanism of endothelial dysfunction caused by the HBP, which may contribute to the accelerated atherosclerosis in diabetes, as observed in ApoE-/-mice treated with GlcN. 27, 29 The mechanism of eNOS uncoupling mediated by p38 mapk in response to GlcN remains unknown at this stage and warrants further investigation. Nevertheless, the present results further illustrate that p38 mapk might be a potential target for treatment of endothelial dysfunction under various pathological conditions. Indeed, the role of p38 mapk in endothelial dysfunction has been recently demonstrated in vitro as well as in vivo. Exposure of endothelial progenitor cells isolated from healthy adult subjects to uremic solute p-cresol to mimic uremic condition in patients, enhances p38 mapk activity and impairs the angiogenesis capacity of the cells, which can be prevented by the p38 mapk inhibitor SB203580. 45 p38 mapk activity has also been found to be increased in endothelial progenitor cells from patients with coronary artery disease, and inhibition of p38 mapk increases the number of endothelial progenitor cells from these patients. 46 Importantly, a recent clinical study demonstrated that p38 mapk inhibitor is able to improve endothelial function in hypercholesterolemic patients, 47 and reduces atherosclerotic lesion progression in ApoE-/-mice. 48 Enhanced p38 mapk activity has also been found in adipocytes from type II diabetic patients 49 and in the heart of high-fat diet-fed rats. 50 Our studies, together with others, have important clinical implications. First, GlcN is widely used as a supplement to treat osteoarthritis, and the efficacy of GlcN remains uncertain. 23 The detrimental effects of GlcN on endothelial function may have to be considered. The standard dosage of GlcN used orally in patients is 1,500 mg/day, which equates to a plasma concentration of 10 μmol/L. 51 This concentration is clearly lower than that used in the present study in vitro. The fact that 0.1-1 mmol/L of GlcN in vitro can affect endothelial function in a very short time (Figure 1) , and that patients are treated chronically for years on a daily basis, suggest that there are still some concerns about the possible adverse effects of the clinical use of GlcN, which should be clarified in future longterm clinical trials, as suggested by some authors. 51 Second, the HBP pathway is involved in endothelial dysfunction and glucotoxicity in diabetes mellitus. The present findings further support the role of the HBP pathway in diabetic vascular complications. And third, p38 mapk is involved in multiple cellular abnormalities including metabolic stress, inflammatory responses, endothelial PAI-1 expression, and endothelial dysfunction; the present study reinforces the ongoing clinical trials, which are designed to investigate clinical outcomes in patients with cardiovascular diseases treated with p38 mapk inhibitors (Clinical Trial Nr. ClinicalTrials.gov Identifier: NVT00570752 and NCT00910962).
